Booze warnings on hold
Photo:
123RF
Outdated alcohol guidelines put New Zealand out of step with modern research, but our health authorities are in no hurry to update them.
In Canada, proposed guidelines for low-risk drinking set the weekly limit at two drinks.
Here in New Zealand, the recommendation is to cap alcohol at 10 drinks weekly for women, and 15 for men, with two alcohol-free days per week.
Despite these guidelines being nearly 15 years old, and documents from Health NZ showing that they consider a review of the guidelines to be 'necessary', for now, the guidelines are staying as they are.
"The complication is that the Ministry of Health has come in over the top of [Health NZ] and has said 'actually these are our guidelines ... we want to control this and we're putting a pause on that work'," says RNZ's Guyon Espiner.
"It certainly does show that they're listening to the alcohol industry, who are pretty exercised about this - because as you can imagine, this could have a significant effect on sales if people did take this advice and did drink significantly less."
In a series of articles over the past few months, Espiner has reported on issues of
alcohol harm
and how the
alcohol lobby
has
impacted policy
in New Zealand.
Through documents he received through the
Official Information Act (OIA)
, he found that Health NZ commissioned a review of the low-risk guidelines. But in October 2024, a lobbyist emailed Ross Bell, who is a manager in the Ministry of Health's Public Health Agency, asking why Health NZ's website said the guidelines were under review.
In December, following a second email which again asked about the review and also complained about mention of the Canadian guidelines on Health NZ-run website 'alcohol.org.nz', Bell emailed Health NZ saying "All work on this project will now pause. You will update relevant Health NZ websites to remove references to the review and also to other jurisdictions' guidelines (including the Canadian one)."
But in a statement to The Detail, the Ministry of Health says it "understands Health New Zealand has continued some work related to the review. The Ministry is working with Health New Zealand on potential next steps, including how Health New Zealand's progress on the review to date can be used to inform any future work in this area" and that "the Ministry is currently considering where the next phase (Phase 2) will fit as it prioritises its work programme for 2025/26."
The Ministry's statement, which is attributed to Dr Andrew Old, Deputy Director-General, Public Health Agency, goes on to say that "as part of good policy process, the Ministry engages with a broad range of interested parties-including community organisations, public health experts, and the industry-to ensure any regulatory approaches are well-informed and transparent. Reference to the drinking guidelines review was removed from the alcohol.org.nz website to avoid confusion about roles and responsibilities as the guidelines are now led by the Ministry of Health - rather than Health New Zealand which has responsibility for the alcohol.org.nz site. This was an internal Ministry decision."
In today's episode of The Detail, Espiner details other examples of contact between the alcohol lobby and health policy makers.
"The material I've got shows that yes they've had a lot of meetings, a lot of email contact, in fact one looked like a regular meeting between alcohol lobbyists and Ministry of Health staff. They've also shared with the alcohol industry their plans on how they will combat Fetal Alcohol Spectrum Disorder ... they shared that entire draft document with them and also shared with them plans about how they might spend the alcohol levy."
Espiner says that while this contact is going on, tobacco lobbyists are completely 'locked out of the policy process".
"We're signatory to the Framework Convention on Tobacco Control, [which is] a World Health initiative, and there's a clause in there that New Zealand is signed up to that says you won't allow the vested interests of the tobacco industry to shape policy.
"What's interesting is that the alcohol industry has escaped most of that scrutiny."
For Massey University associate professor Andy Towers, who has worked on the Health NZ review, it is a clear mistake for New Zealand to allow lobbyists a role.
"It's very, very clear that you don't invite the wolf into the henhouse," he says.
"Unfortunately the alcohol industry makes money based on alcohol use and resulting alcohol harms and in a space where we are trying to reduce the harmful use of alcohol and reduce those harms for society and for communities, there is not space for the alcohol industry there. They do not get to sit at the table, just as you wouldn't invite an arms manufacturer to the table to talk about cessation of violence."
In this episode of The Detail, Towers explains how knowledge around the harm of alcohol has evolved in the past 20 years, and where New Zealand sits on alcohol use compared to other countries.
Check out how to listen to and follow The Detail
here
.
You can also stay up-to-date by liking us on
or following us on
.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
RNZ News
8 minutes ago
- RNZ News
'Awful error': Two-month-old dies following overdose after pharmacy allegedly gives medication at wrong dosage
By Sam Sherwood, Bellamere Duncan died at Starship Hospital on 19 July. Photo: Supplied Warning: This story has details of the death of an infant A two-month-old baby died following an overdose after she was allegedly given medication at an adult dosage by a pharmacy, RNZ can reveal. In an exclusive interview, her grieving parents are calling for a law change that would make it mandatory for medication to be checked by two people before it is dispensed. The revelations have prompted the Ministry of Health and Health New Zealand to "urgently" undertake a joint review into the incident, with Medsafe visiting the pharmacy to ensure they are safe to continue operating. The Pharmacy Council, which is also investigating, says it is "clear that an awful error has occurred". Bellamere Arwyn Duncan was born at 31 weeks and five days at Palmerston North Hospital on 2 May. Her parents Tempest Puklowski and Tristan Duncan knew from the scans she was going to be "quite tiny", and were told she would be early but no one expected she would come as early as she did. "That was definitely on her own accord," Puklowski, a first-time mum, says. "She sort of just made up her mind, and was like 'I'm coming out'." Bellamere, who weighed 1023 grams when she was born, spent about two months in the neonatal unit. Puklowski says she could not wait to bring her baby home and was excited when she was discharged on 24 June. Do you know more? Email While in hospital, Puklowski gave Bellamere her drops for Vitamin D. Nurses also administered her phosphate. When they left hospital they were given some Vitamin D in a little bottle, and a prescription for iron and Vitamin D. The following day Duncan went to a Manawatu pharmacy with the prescriptions. He was given the iron, but says the pharmacy refused to give the Vitamin D as the staff thought the dosage was "too high for her age and her weight". The staff said they would call the neonatal unit and follow-up. A few days later Puklowski received a call from the unit to organise a home care visit. During the call she was asked if she had any concerns, and Puklowski asked if they had been contacted about the Vitamin D. They had not, and said they would follow up and rewrite the prescription along with a prescription for phosphate. The homecare visit went well. Bellamere had put on weight, and was "doing well", Puklowski recalls. "She was settling in perfect." Bellamere Duncan's parents were allegedly given an adult dosage of phosphate by the pharmacy. Photo: Supplied A day after the phone call, on 2 July, Duncan went to the pharmacy to collect the medication and came home with just the phosphate. Unbeknown to the parents, they had allegedly been given an adult dosage of phosphate. The label on the medication directed them to dissolve one 500mg tablet of phosphate twice daily in a glass of water. Puklowski said given the pharmacy's refusal to give them the Vitamin D, they did not even think to question the dosage. That evening they gave Bellamere her first dose of the medicine in her formula water. They would give her three bottles in 24 hours as was recommended. The couple noticed in that period that her eating was off, and thought she was "extra gassy", Puklowski says. "She was still feeding fine. She just wasn't maybe going through a whole bottle compared to what she was," she recalls. Then, the day after she got her first dosage, Bellamere suddenly stopped breathing. "We were like oh shit, I went straight into panic," Puklowski says. "Tristan had to start administering CPR, and I was on the phone to the ambulance which arrived very quickly, within at least five to 10 minutes." Bellamere was flown to Starship Hospital after she suddenly stopped breathing. Photo: RNZ / Cole Eastham-Farrelly Bellamere was taken to hospital and rushed to the emergency department. Once she was stabilised she was taken to the neonatal unit where she stayed overnight before she was flown to Starship Hospital. "We were definitely terrified and more confused than anything about what was going on," Puklowski says. The couple told the doctors they were worried they had overfed her, and her body was struggling to get it out. "I was trying to think of what had changed in the past 24 hours, which was her phosphate," Puklowski says. The couple had taken a bottle of the medicine with them to Starship Hospital. She gave it to the staff who saw that they had been given an adult dose. The staff then requested the original prescription which confirmed the script had been written with the correct dosage, but somehow the pharmacy had given the wrong dosage, Puklowski says. "I keep thinking about how much she ended up having and it just makes me feel sick." Once at Starship Hospital the couple were told they would "have to make some hard decisions". "But then we went and saw her. She was still moving and her eyes were still opening. "So we were like, 'No. She's our strong little fighter. I mean, look at how well she's done so far'." Tragically, Bellamere died at Starship Hospital on 19 July. "It was completely horrible," Puklowski says of having to say goodbye to her baby. A preliminary coroner's opinion is that Bellamere died of phosphate toxicity, her parents confirmed. A week on from their daughter's death, the couple are still in shock. Puklowski says she is in "disbelief". "They're just numb," Puklowski's mother, Rachelle Puklowski says. "It's completely traumatised them. They just watched Bella pass twice, once in their home and then again up at the hospital." The owner of the Manawatu pharmacy that dispensed the medication said in a statement to RNZ the baby's death was "a tragedy". "Our sympathy is with the family and whānau. This is a very difficult time. "We are looking into what has happened to try to understand how this took place. There will also be external reviews which we will work with." RNZ asked the owner how the medication was given at the wrong dosage, whether they disputed the allegations, when the pharmacy became aware the wrong dosage had been given, and what confidence people could have about other medication received from the pharmacy. The owner said the pharmacy was "devastated about what has happened and are investigating to find out how this occurred". "It is not appropriate to comment further at this stage." Duncan describes what happened to his daughter as "negligence". "How was it overlooked?" Puklowski wants to know. "Not even just in the initial making of it, but in the handing of it to us. They denied us the Vitamin D because they thought the dosage was too high for her age and weight, but can proceed to give us a full adult dosage of phosphate, like it just makes no absolute sense," she said. "They have to make sure they realise the kind of mistake that they have made, and that something has been done about it." The couple are adamant they want changes to the system for giving out medication. "It's the sort of thing that can't really be overlooked. "There needs to be something better in effect, rather than just relying on one person to make sure you're getting the right prescription, having at least a few eyes." Pharmacy Council chief executive Michael Pead said in a statement to RNZ the council's "heartfelt thoughts" were with Bellamere's family following the "absolute tragedy". "It is clear that an awful error has occurred, and as the regulator for pharmacists, we are working on understanding every detail of what happened, what went wrong, how it went wrong, and who was involved. The Pharmacy Council is working promptly to take any immediate steps required to ensure public safety. "Our enquiry and investigation processes are currently underway and, until these are complete, we cannot provide any further details. At the end of the process, we will make any recommended changes to ensure as best as possible an event like this does not happen again." The Pharmacy Council operated within a wider framework of organisations responsible for the protection of public health and safety, Pead said. "We have also referred the incident to other relevant organisations to ensure they can act on any matters that may fall into their remit. "We would emphasise that situations of this nature are extremely rare. No health practitioner goes to work aiming to cause harm, and New Zealanders can have faith that the pharmacists working in their communities and hospitals are vigilant about medicine dosage and patient safety." Pead said the council set the standard that all pharmacists follow a "logical, safe and methodical procedure" to dispense therapeutic products. Every pharmacy would have their own standard operating procedures that covered the dispensing and checking process, he said. "It involves checking the prescription for legality and eligibility, clinical assessment and accuracy check. "The check by a second person (separation of dispenser and checker roles) is considered best practice and is often built into the checking process in a pharmacy's procedures. The pharmacist is responsible for the final check. Sometimes this may not be possible for a sole charge pharmacist, working alone in the dispensary. It is recommended that a second self-check should be carried out, taking a few moments between the prescriptions to 'reset' and performing the final check with care." Health New Zealand and the Ministry of Health released a joint statement to RNZ, extending their "heartfelt condolences" to Bellamere's family. "Health New Zealand and the Ministry of Health take very seriously incidents like these, which while rare, are always thoroughly investigated to identify any lessons that can be learned. "Both agencies involved are acting urgently in undertaking a joint review into this incident, exploring all aspects of the care provided." Health New Zealand is undertaking a serious incident review and the Ministry of Health will be looking at actions taken by health services in the community. "This will occur alongside providing any information requested by the coroner." On Friday, a Ministry of Health spokesperson told RNZ that Medsafe had visited the pharmacy where the medicine was dispensed and completed an initial assessment that the pharmacy was safe to continue operating. "That initial assessment is part of a rapid audit and site visit of the pharmacy which is being carried out by Medsafe, aimed to provide additional assurance that the pharmacy is meeting expected standards." The actions taken by Medsafe and the Pharmacy Council would help inform the ongoing review, the spokesperson said. "These measures are occurring alongside providing any information requested by the coroner." Health Minister Simeon Brown said in a statement to RNZ he was "heartbroken" for Bellamere's family who had "inexplicably lost their baby in tragic circumstances". "My thoughts are with them at this incredibly difficult time. "I am advised that the Pharmacy Council has taken immediate action and is investigating this incident. The council has also advised other appropriate regulators."
RNZ News
8 hours ago
- RNZ News
Medsafe considers crackdown on import of unregulated peptide medications
Medsafe says people are buying unregulated peptides from websites that make health claims for which there is little or no evidence. Photo: Science Photo Li / WBU / Science Photo Library via AFP New Zealanders are buying potentially high-risk, unregulated peptide medications from overseas websites to treat sexual dysfunction, memory loss and more. Medsafe is considering a crackdown, warning many are sold based on unproven claims. It hopes to have several of them - and similar ones that may crop up - classified as prescription medicines, making it illegal to import them without a prescription. In a written submission to the Medicines Classification Committee, Medsafe said peptides were being bought from websites that made claims they could help with "cognitive enhancement, hair growth, libido enhancers, sexual dysfunction, immune enhancers and cancer treatment", and more. However, there was often little, if any, evidence to back up the claims. Most had not been tested for safety and efficacy on humans. Medsafe could not seize peptides at the border, if they were not classed as prescription medicine. Instead, it released the products to the purchasers with a "high-risk medicine letter". "This is posing a risk to health, as the product's quality, efficacy and interactions with other medicines is unknown," the submission said. Because new peptide substances were created all the time, Medsafe asked the committee to class whole groups of them as prescription medicines, so future versions that fell within the group would still be covered. Many websites that sold peptides claimed to sell them "for research purposes", but customers intended to use them therapeutically, the submission said. Fifty-six parcels were intercepted at the border in the year to May, containing peptides or prescription medications known as selective androgen receptor modulators (SARMS). Customs said it couldn't say how many got through without interception. Medsafe said the classification review would take into consideration the safety and appropriateness of being able to import these products, as well the risks of limiting access. The committee considered the submission at a meeting on Wednesday and its decision has not been made public yet. The final decision on medicine classification changes will be made by the Minister of Health at the committee's recommendation. Sign up for Ngā Pitopito Kōrero , a daily newsletter curated by our editors and delivered straight to your inbox every weekday.
NZ Herald
21 hours ago
- NZ Herald
Waikato med school business case beats Auckland and Otago
Option 2 was a specialist medical training programme focused on rural health run by those two universities and was estimated to cost $10.2b, while option 3, the new medical school at Waikato, was estimated to cost $9.1b, making it the cheapest overall – although the University of Auckland has criticised the assumptions behind this costing. Director-General of Health Dr Diana Sarfati and University of Waikato vice-chancellor Professor Neil Quigley, watched by Health Minister at the time, Shane Reti, and Prime Minister Christopher Luxon, signing the Memorandum of Understanding for a third medical school in 2024. Photo / Mark Mitchell The Waikato medical school was also estimated to deliver greater benefits, leading to a benefit-cost ratio of 1.99, meaning each dollar spent on the school produced $1.99 in benefit. Option 1 and 2 had a ratio of 1.5 and 1.8 – placing them only narrowly behind Waikato. Health Minister Simeon Brown told the Herald the school was a 'game-changer for the long-term growth of our medical workforce in New Zealand'. 'Cabinet agreed to this proposal following the Ministry of Health undertaking a business case and a cost-benefit analysis which demonstrated this proposal would be the most effective at building this critical health workforce for New Zealand,' he said. The University of Auckland's Dean of Medical and Health Sciences Professor Warwick Bagg told the Herald he was 'deeply concerned' by the business case, which seemed to have a predetermined outcome: to favour the Waikato medical school the National Party took to the last election. He said the assumptions of the report were flawed. The capital cost for the new school at Waikato of $232 million was far greater than the other two options, which had costs of $49m and $81.5m respectively. The ongoing operational costs racked up over the years 2026 to 2042 were higher for the first two options, at $513.6m and $508m compared with $361.6m at Waikato. Bagg said this modelling made unfair and inaccurate assumptions about the existing two medical schools that put them at a disadvantage. For example, the business case said that it is 'more certain that Option 3, the Waikato school, has a lower operating cost … simply due to it being a shorter programme'. While it is correct that the Waikato Medical School is a shorter programme, tailored to just graduates, the students admitted the school will still have to offer an undergraduate programme somewhere, probably in New Zealand, which the Government will have to subsidise. Bagg said the cost of turning Waikato's students into graduates who can be admitted into the school isn't reflected in the business case. Lifting those costs out of the business case made Waikato look better overall. 'They are focused on the four-year graduate programme … they haven't focused on the three years that they'll have to do to get into that medical school,' he said. He said another way the high capital costs for Waikato have been 'offset' is the business case has found 'more benefits for the Waikato medical school'. The business case is particularly reliant on the assumption that far more Waikato graduates will go on to be GPs – and GPs who work rurally – than graduates of other schools. The business case found increasing capacity at the existing medical schools would result in just 23% of those graduates staying on to become GPs, while the joint rural training programme would result in 33% of its graduates becoming GPs. In the Waikato medical school's case, 38% of its graduates would become GPs. The business case notes that having a higher number of GPs in the community increases people's health. The fact the Waikato school provides the greatest number of GPs therefore weighs heavily in its favour. Benefits and costs of the three options analysed. Table / Ministry of Health Bagg said Sapere, who provided cost-benefit analysis for the business case, 'haven't used the data we provided them' to calculate the GP figure for the option of increasing capacity at Auckland And Otago. He said 'about 35%' of graduates from Auckland and Otago medical schools are working as GPs eight years after graduating – a far higher figure than the 23% quoted in the business case. He said this lower figure came from a survey of graduates' intentions when they graduated, not what they actually ended up doing. 'We told Sapere this assumption was incorrect,' he said. The assumptions for the number of GPs graduating from Waikato were based on figures from Australia's University of Wollongong Graduate School of Medicine, which will be a model for the Waikato school. Brown defended the modelling behind the business case. He said the school will 'offer a post-graduate medical qualification based on similar successful programmes in Australia'. 'These programmes include a year-long primary care placement and encourage students to work in primary care settings following graduation. The selection criteria of students alongside their long-term placements in primary care will both support a higher degree of these medical students to work in primary care after graduation,' he said. No expectation of ratepayer funding for med school – Brown Brown poured cold water on concerns councils could be asked to stump up for the new school. Brown's Cabinet paper suggested territorial authorities – local councils – are being lined up for a contribution to the school. A paragraph from the Cabinet paper progressing the school, which will be joint-funded by the Crown, the university and philanthropists, noted, '[t]he University of Waikato has identified $151.859 million which they will ... contribute towards the new medical school costs'. 'This contribution shows significant support for a new medical school from a range of stakeholders from private trusts and foundations, individuals, and territorial authorities'. But Brown told the Herald, 'as Minister of Health, I have no expectation that councils will financially contribute to the new Waikato Medical School'. University of Waikato vice-chancellor Neil Quigley told the Herald earlier this week about half of the university's $150m share of the school could come from donations. 'At the moment, we're well on the way to the 50% of donations just with a relatively small number of large trusts and very wealthy individuals so we don't see that as particularly challenging,' he said. Brown defends information release Labour's health spokeswoman Ayesha Verrall called for the business case to be published on Monday to show the assumptions underlying Cabinet's decision to proceed with the school. 'Treasury has raised concerns about this project. Decisions about the future of NZ's medical workforce are critical and must be transparent. The Government needs to release the costings quickly,' Verrall said. The business case was published by the Ministry of Health about 6pm on Friday, a time often associated with the Government trying to bury information because people are enjoying their weekend. Brown defended the timing of the release, saying: 'Cabinet made the decision to progress with the third medical school on Monday with officials tasked with preparing material for proactive release following this decision. 'Normally Cabinet decisions and supporting information are required to be proactively released 30 days following a decision, however due to the significant interest in this decision, this was sped up to ensure the information could be made available as quickly as possible.'
